D. Hidalgo

1 works

Ikena Oncology, Translational Research, Boston, USA;

1. IK930, a novel TEAD inhibitor, sensitizes KRAS and EGFR mutant tumors to oncogene targeted therapy

   M. Rajurkar, Manuel Sánchez‐Martín, D. Hidalgo +5

   ArticleHippo pathway signaling and YAP/TAZEuropean Journal of Cancer20220 citations

   ABIABI:AkademIndex/openalex/2022.article.000518